Welcome to our dedicated page for Sonnet Biotherapeutc Hldng SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Sonnet BioTherapeutics Holdings, Inc. (historically trading under the ticker SONN). These documents record the company’s regulatory history as an oncology-focused biotechnology issuer and capture key events such as shareholder meetings, financing transactions, and the business combination with Hyperliquid Strategies Inc. that resulted in Sonnet becoming a wholly owned subsidiary of a new Nasdaq-listed entity.
Investors can use Sonnet’s Form 8‑K filings to track material developments. Recent 8‑Ks describe, among other items, the entry into a Business Combination Agreement with Rorschach I LLC and Hyperliquid Strategies Inc., the structure of the mergers that formed Hyperliquid Strategies Inc. as the parent company, and subsequent confirmations of Nasdaq listing compliance. Other 8‑Ks detail private placements of preferred stock and warrants, the issuance of convertible notes and associated warrants, and employment agreements and compensation arrangements for senior executives.
The company’s Definitive Proxy Statement on Schedule 14A outlines matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, auditor ratification, and the logistics of virtual annual meetings. These materials also provide information about board composition, governance practices, and the proposals that required shareholder approval in connection with major transactions.
Through Sonnet’s periodic and current reports, readers can understand how the company structured the business combination with Hyperliquid Strategies Inc., including the planned issuance of Pubco (Hyperliquid Strategies Inc.) common stock, contingent value rights (CVRs) related to Sonnet’s biotech assets, and the anticipated ownership percentages of legacy Sonnet stockholders versus new investors. Filings also describe responses to Nasdaq stockholders’ equity requirements and the company’s efforts to maintain listing standards prior to the corporate reorganization.
On Stock Titan, these filings are complemented by AI-powered tools that summarize lengthy documents and highlight key terms, helping users interpret complex sections of 8‑Ks, proxy statements, and related agreements. Real-time updates from the SEC’s EDGAR system allow users to see new filings as they are posted, while structured views of items such as financing terms and governance proposals make it easier to compare disclosures across documents. For historical research on SONN and its transition into a subsidiary of Hyperliquid Strategies Inc. (whose stock is expected to trade under the ticker PURR), this page serves as a central reference for the company’s official regulatory record.